ClinicalTrials.gg
CompletedNCT02340819Updated Jun 9, 2021Results posted

Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome (SBS)

A Phase 3 interventional study of Teduglutide in Short Bowel Syndrome, sponsored by Shire. Completed at 5 sites in Japan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-06-09.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.

Enrollment
13th of 20
11 · median 20
Started
2014
with 1 other
Phase 3
16 of 20
none open now
Registered
9th of 20
by date
Lead sponsor
13 of 20
Shire

Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 13th largest by enrollment, is one of 2 that started in 2014, is one of 16 in phase 3, and was the 9th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About teduglutide

teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing teduglutide in Short Bowel Syndrome, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of an investigational treatment (teduglutide) in Japanese patients with PN-dependent SBS. This study will also look at how teduglutide moves through the body (pharmacokinetics).

03

Conditions studied

  • Short Bowel Syndrome

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

This study has 3 stages, consisting of an optimization/stabilization period (Stage 1), a 24-week treatment period in which all patients will receive teduglutide (Stage 2), and a long-term extension (Stage 3).

During the long-term extension (Stage 3), patients will continue to receive teduglutide for up to an additional 24 months or until teduglutide is commercially available, whichever comes earlier.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Arm 1

    0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.

    Drug: Teduglutide

Interventions

  • 0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.

06

What researchers measure

Primary outcomes

  1. Stage 2: Absolute Change From Baseline in Weekly Parenteral Support (PS) Volume at Week 24

    Absolute change from baseline in weekly PS volume at Week 24 was reported.

    Time frame: Baseline (stage 2), Week 24

  2. Stage 2: Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at Week 24

    Percent change from baseline in weekly PS volume at Week 24 was reported.

    Time frame: Baseline (stage 2), Week 24

  3. Stage 2: Percentage of Participants Who Demonstrate Response to Teduglutide at End of Stage 2

    Response was defined as the achievement of at least a 20% reduction from baseline (Visit 2) in weekly PS volume at Week 20 and again at Week 24.

    Time frame: End of Stage 2 (up to Week 24)

  4. Stage 2: Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at Week 24

    Absolute change from baseline in number of days per Week of PS usage at Week 24 was reported.

    Time frame: Baseline (stage 2), Week 24

  5. Stage 2: Absolute Change From Baseline in Plasma Citrulline Levels at Week 24

    Plasma citrulline was measured as an assessment of enterocyte mass. Absolute change from baseline in plasma citrulline levels at Week 24 was reported.

    Time frame: Baseline (stage 2), Week 24

  6. Stage 2: Percent Change From Baseline in Plasma Citrulline Levels at Week 24

    Plasma citrulline was measured as an assessment of enterocyte mass. Percent change from baseline in plasma citrulline at Week 24 was reported.

    Time frame: Baseline (stage 2), Week 24

  7. Stage 2: Number of Participants Who Achieved Enteral Autonomy at Week 24

    Enteral autonomy was defined as no prescribed PS and no use of PS recorded in the participant diary at the end of stage 2. Number of participants who achieved enteral autonomy at Week 24 was reported.

    Time frame: Week 24

  8. Stage 3: Absolute Change From Baseline in Weekly Parenteral Support (PS) Volume at Extension Month 24

    Absolute change from baseline in weekly PS volume at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.

    Time frame: Baseline (stage 3), Extension Month 24

  9. Stage 3: Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at Extension Month 24

    Percent change from baseline in weekly PS volume at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.

    Time frame: Baseline (stage 3), Extension Month 24

  10. Stage 3: Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at Extension Month 24

    Absolute change from baseline in number of days per Week of PS usage at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.

    Time frame: Baseline (stage 3), Extension Month 24

  11. Stage 3: Absolute Change From Baseline in Plasma Citrulline Levels at Extension Month 24

    Plasma citrulline was measured as an assessment of enterocyte mass. Absolute change from baseline in plasma citrulline levels at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.

    Time frame: Baseline (stage 3), Extension Month 24

  12. Stage 3: Percent Change From Baseline in Plasma Citrulline Levels at Extension Month 24

    Plasma citrulline was measured as an assessment of enterocyte mass. Percent change from baseline in plasma citrulline at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.

    Time frame: Baseline (stage 3), Extension Month 24

  13. Stage 4: Absolute Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment

    Absolute change from baseline in weekly PS volume at end of treatment was reported.

    Time frame: Baseline (stage 4), End of Treatment (up to 47 months)

  14. Stage 4: Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment

    Percent change from baseline in weekly PS volume at end of treatment was reported.

    Time frame: Baseline (stage 4), End of Treatment (up to 47 months)

  15. Stage 4: Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at End of Treatment

    Absolute change from baseline in number of days per week of PS usage at end of treatment was reported.

    Time frame: Baseline (stage 4), End of Treatment (up to 47 months)

  16. Stage 4: Absolute Change From Baseline in Plasma Citrulline Levels at End of Treatment

    Plasma citrulline was measured as an assessment of enterocyte mass. Absolute change from baseline in plasma citrulline levels at end of treatment was reported.

    Time frame: Baseline (stage 4), End of Treatment (up to 47 months)

  17. Stage 4: Percent Change From Baseline in Plasma Citrulline Levels at End of Treatment

    Plasma citrulline was measured as an assessment of enterocyte mass. Percent change in plasma citrulline from baseline at end of treatment was reported.

    Time frame: Baseline (stage 4), End of Treatment (up to 47 months)

Secondary outcomes

  1. Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-Inf) of Teduglutide in Plasma

    Area under the concentration-time curve from time zero to infinity of teduglutide in plasma were evaluated.

    Time frame: Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose

  2. Area Under the Concentration-Time Curve From Time Zero to the Last Time Point (AUC0-t) of Teduglutide in Plasma

    Area under the concentration-time curve from time zero to the last time point of teduglutide in plasma were evaluated.

    Time frame: Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose

  3. Maximum Concentration (Cmax) of Teduglutide in Plasma

    Maximum concentration of teduglutide in plasma were evaluated.

    Time frame: Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose

  4. Time to Reach Maximum Observed Drug Concentration (Tmax) of Teduglutide in Plasma

    Time to reach maximum observed drug concentration of teduglutide in plasma was evaluated.

    Time frame: Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose

  5. Terminal Half-Life (t1/2) of Teduglutide in Plasma

    Terminal half-life of teduglutide in plasma were evaluated.

    Time frame: Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose

  6. Apparent Clearance (CL/F) of Teduglutide in Plasma

    Apparent clearance of teduglutide in plasma were evaluated.

    Time frame: Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose

  7. Apparent Volume of Distribution (Vz/F) of Teduglutide in Plasma

    Apparent volume of distribution of teduglutide in plasma were evaluated.

    Time frame: Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose

07

Results

Posted Nov 20, 2019

Participant flow

The study was conducted at five centers in Japan between 18 December 2014 (first participant first visit) and 12 November 2018 (last participant last visit).

Participant flow — Overall Study
MilestoneTeduglutide
Started11
Started stage 211
Completed stage 29
Started stage 38
Completed stage 37
Started stage 47
Completed stage 47
Completed7
Not completed4
Withdrew: Adverse event1
Withdrew: Withdrawal by subject2
Withdrew: Discontinued with other reason1

Outcome measures

PrimaryStage 2: Absolute Change From Baseline in Weekly Parenteral Support (PS) Volume at Week 24

Absolute change from baseline in weekly PS volume at Week 24 was reported.

Time frame:
Baseline (stage 2), Week 24
Reported as:
Mean · Liter per week (L/week)
Stage 2: Absolute Change From Baseline in Weekly Parenteral Support (PS) Volume at Week 24
Liter per week (L/week)Teduglutide
Stage 2: Absolute Change From Baseline in Weekly Parenteral Support (PS) Volume at Week 24-4.92 ± 4.749
PrimaryStage 2: Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at Week 24

Percent change from baseline in weekly PS volume at Week 24 was reported.

Time frame:
Baseline (stage 2), Week 24
Reported as:
Mean · Percent change in PS volume
Stage 2: Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at Week 24
Percent change in PS volumeTeduglutide
Stage 2: Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at Week 24-30.07 ± 25.892
PrimaryStage 2: Percentage of Participants Who Demonstrate Response to Teduglutide at End of Stage 2

Response was defined as the achievement of at least a 20% reduction from baseline (Visit 2) in weekly PS volume at Week 20 and again at Week 24.

Time frame:
End of Stage 2 (up to Week 24)
Reported as:
Number · Percentage of Participants
Stage 2: Percentage of Participants Who Demonstrate Response to Teduglutide at End of Stage 2
Percentage of ParticipantsTeduglutide
PS Response: Yes45.5
PS Response: No54.5
PrimaryStage 2: Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at Week 24

Absolute change from baseline in number of days per Week of PS usage at Week 24 was reported.

Time frame:
Baseline (stage 2), Week 24
Reported as:
Mean · Days per week (days/week)
Stage 2: Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at Week 24
Days per week (days/week)Teduglutide
Stage 2: Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at Week 24-1.0 ± 1.80
PrimaryStage 2: Absolute Change From Baseline in Plasma Citrulline Levels at Week 24

Plasma citrulline was measured as an assessment of enterocyte mass. Absolute change from baseline in plasma citrulline levels at Week 24 was reported.

Time frame:
Baseline (stage 2), Week 24
Reported as:
Mean · Micromoles per liter
Stage 2: Absolute Change From Baseline in Plasma Citrulline Levels at Week 24
Micromoles per literTeduglutide
Stage 2: Absolute Change From Baseline in Plasma Citrulline Levels at Week 2415.0 ± 17.37
PrimaryStage 2: Percent Change From Baseline in Plasma Citrulline Levels at Week 24

Plasma citrulline was measured as an assessment of enterocyte mass. Percent change from baseline in plasma citrulline at Week 24 was reported.

Time frame:
Baseline (stage 2), Week 24
Reported as:
Mean · Percent change
Stage 2: Percent Change From Baseline in Plasma Citrulline Levels at Week 24
Percent changeTeduglutide
Stage 2: Percent Change From Baseline in Plasma Citrulline Levels at Week 2486.9 ± 112.33
PrimaryStage 2: Number of Participants Who Achieved Enteral Autonomy at Week 24

Enteral autonomy was defined as no prescribed PS and no use of PS recorded in the participant diary at the end of stage 2. Number of participants who achieved enteral autonomy at Week 24 was reported.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Stage 2: Number of Participants Who Achieved Enteral Autonomy at Week 24
ParticipantsTeduglutide
Stage 2: Number of Participants Who Achieved Enteral Autonomy at Week 240
PrimaryStage 3: Absolute Change From Baseline in Weekly Parenteral Support (PS) Volume at Extension Month 24

Absolute change from baseline in weekly PS volume at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.

Time frame:
Baseline (stage 3), Extension Month 24
Reported as:
Mean · L/week
Stage 3: Absolute Change From Baseline in Weekly Parenteral Support (PS) Volume at Extension Month 24
L/weekTeduglutide
Stage 3: Absolute Change From Baseline in Weekly Parenteral Support (PS) Volume at Extension Month 24-8.33 ± 5.940
PrimaryStage 3: Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at Extension Month 24

Percent change from baseline in weekly PS volume at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.

Time frame:
Baseline (stage 3), Extension Month 24
Reported as:
Mean · Percent change in PS volume
Stage 3: Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at Extension Month 24
Percent change in PS volumeTeduglutide
Stage 3: Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at Extension Month 24-53.53 ± 33.866
PrimaryStage 3: Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at Extension Month 24

Absolute change from baseline in number of days per Week of PS usage at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.

Time frame:
Baseline (stage 3), Extension Month 24
Reported as:
Mean · days/week
Stage 3: Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at Extension Month 24
days/weekTeduglutide
Stage 3: Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at Extension Month 24-2.1 ± 3.34
PrimaryStage 3: Absolute Change From Baseline in Plasma Citrulline Levels at Extension Month 24

Plasma citrulline was measured as an assessment of enterocyte mass. Absolute change from baseline in plasma citrulline levels at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.

Time frame:
Baseline (stage 3), Extension Month 24
Reported as:
Mean · Micromoles per liter
Stage 3: Absolute Change From Baseline in Plasma Citrulline Levels at Extension Month 24
Micromoles per literTeduglutide
Stage 3: Absolute Change From Baseline in Plasma Citrulline Levels at Extension Month 2428.3 ± 24.05
PrimaryStage 3: Percent Change From Baseline in Plasma Citrulline Levels at Extension Month 24

Plasma citrulline was measured as an assessment of enterocyte mass. Percent change from baseline in plasma citrulline at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.

Time frame:
Baseline (stage 3), Extension Month 24
Reported as:
Mean · Percent change
Stage 3: Percent Change From Baseline in Plasma Citrulline Levels at Extension Month 24
Percent changeTeduglutide
Stage 3: Percent Change From Baseline in Plasma Citrulline Levels at Extension Month 24135.0 ± 84.17
PrimaryStage 4: Absolute Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment

Absolute change from baseline in weekly PS volume at end of treatment was reported.

Time frame:
Baseline (stage 4), End of Treatment (up to 47 months)
Reported as:
Mean · L/week
Stage 4: Absolute Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment
L/weekTeduglutide
Stage 4: Absolute Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment-5.08 ± 6.404
PrimaryStage 4: Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment

Percent change from baseline in weekly PS volume at end of treatment was reported.

Time frame:
Baseline (stage 4), End of Treatment (up to 47 months)
Reported as:
Mean · Percent change in PS volume
Stage 4: Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment
Percent change in PS volumeTeduglutide
Stage 4: Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment-34.12 ± 38.877
PrimaryStage 4: Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at End of Treatment

Absolute change from baseline in number of days per week of PS usage at end of treatment was reported.

Time frame:
Baseline (stage 4), End of Treatment (up to 47 months)
Reported as:
Mean · days/week
Stage 4: Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at End of Treatment
days/weekTeduglutide
Stage 4: Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at End of Treatment-1.4 ± 2.80
PrimaryStage 4: Absolute Change From Baseline in Plasma Citrulline Levels at End of Treatment

Plasma citrulline was measured as an assessment of enterocyte mass. Absolute change from baseline in plasma citrulline levels at end of treatment was reported.

Time frame:
Baseline (stage 4), End of Treatment (up to 47 months)
Reported as:
Mean · Micromoles per liter
Stage 4: Absolute Change From Baseline in Plasma Citrulline Levels at End of Treatment
Micromoles per literTeduglutide
Stage 4: Absolute Change From Baseline in Plasma Citrulline Levels at End of Treatment19.3 ± 19.96
PrimaryStage 4: Percent Change From Baseline in Plasma Citrulline Levels at End of Treatment

Plasma citrulline was measured as an assessment of enterocyte mass. Percent change in plasma citrulline from baseline at end of treatment was reported.

Time frame:
Baseline (stage 4), End of Treatment (up to 47 months)
Reported as:
Mean · Percent change
Stage 4: Percent Change From Baseline in Plasma Citrulline Levels at End of Treatment
Percent changeTeduglutide
Stage 4: Percent Change From Baseline in Plasma Citrulline Levels at End of Treatment110.3 ± 98.13
SecondaryArea Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-Inf) of Teduglutide in Plasma

Area under the concentration-time curve from time zero to infinity of teduglutide in plasma were evaluated.

Time frame:
Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose
Reported as:
Mean · Nanogram*hour per milliliter (ng*h/mL)
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-Inf) of Teduglutide in Plasma
Nanogram*hour per milliliter (ng*h/mL)Teduglutide
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-Inf) of Teduglutide in Plasma204 ± 51.1
SecondaryArea Under the Concentration-Time Curve From Time Zero to the Last Time Point (AUC0-t) of Teduglutide in Plasma

Area under the concentration-time curve from time zero to the last time point of teduglutide in plasma were evaluated.

Time frame:
Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose
Reported as:
Mean · ng*h/mL
Area Under the Concentration-Time Curve From Time Zero to the Last Time Point (AUC0-t) of Teduglutide in Plasma
ng*h/mLTeduglutide
Area Under the Concentration-Time Curve From Time Zero to the Last Time Point (AUC0-t) of Teduglutide in Plasma201 ± 51.6
SecondaryMaximum Concentration (Cmax) of Teduglutide in Plasma

Maximum concentration of teduglutide in plasma were evaluated.

Time frame:
Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose
Reported as:
Mean · Nanogram per milliliter (ng/mL)
Maximum Concentration (Cmax) of Teduglutide in Plasma
Nanogram per milliliter (ng/mL)Teduglutide
Maximum Concentration (Cmax) of Teduglutide in Plasma49.7 ± 19.7
SecondaryTime to Reach Maximum Observed Drug Concentration (Tmax) of Teduglutide in Plasma

Time to reach maximum observed drug concentration of teduglutide in plasma was evaluated.

Time frame:
Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose
Reported as:
Median · hour
Time to Reach Maximum Observed Drug Concentration (Tmax) of Teduglutide in Plasma
hourTeduglutide
Time to Reach Maximum Observed Drug Concentration (Tmax) of Teduglutide in Plasma2.49 (1.17 to 4.00)
SecondaryTerminal Half-Life (t1/2) of Teduglutide in Plasma

Terminal half-life of teduglutide in plasma were evaluated.

Time frame:
Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose
Reported as:
Median · hour
Terminal Half-Life (t1/2) of Teduglutide in Plasma
hourTeduglutide
Terminal Half-Life (t1/2) of Teduglutide in Plasma1.06 (0.62 to 2.63)
SecondaryApparent Clearance (CL/F) of Teduglutide in Plasma

Apparent clearance of teduglutide in plasma were evaluated.

Time frame:
Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose
Reported as:
Mean · liter per hour (L/h)
Apparent Clearance (CL/F) of Teduglutide in Plasma
liter per hour (L/h)Teduglutide
Apparent Clearance (CL/F) of Teduglutide in Plasma14.5 ± 4.09
SecondaryApparent Volume of Distribution (Vz/F) of Teduglutide in Plasma

Apparent volume of distribution of teduglutide in plasma were evaluated.

Time frame:
Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose
Reported as:
Mean · liter
Apparent Volume of Distribution (Vz/F) of Teduglutide in Plasma
literTeduglutide
Apparent Volume of Distribution (Vz/F) of Teduglutide in Plasma27.8 ± 22.5

Adverse events

Collected over From start of study treatment up to end of the study (up to 47 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Teduglutide1/11 (9.1%)7/11 (63.6%)11/11 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventTeduglutide
Device related infectionInfections and infestations7/11
ThrombophlebitisVascular disorders1/11
EnteritisGastrointestinal disorders1/11
EnterocolitisGastrointestinal disorders1/11
Intestinal obstructionGastrointestinal disorders1/11
Device occlusionGeneral disorders1/11
PyrexiaGeneral disorders1/11
Arthritis bacterialInfections and infestations1/11
Catheter site infectionInfections and infestations1/11
SepsisInfections and infestations1/11
Most frequent other events
Showing 10 of 110
Most frequent other events
EventTeduglutide
HeadacheNervous system disorders6/11
PyrexiaGeneral disorders5/11
NasopharyngitisInfections and infestations5/11
ArthralgiaMusculoskeletal and connective tissue disorders4/11
Abdominal painGastrointestinal disorders4/11
Abdominal distensionGastrointestinal disorders3/11
DiarrhoeaGastrointestinal disorders3/11
NauseaGastrointestinal disorders3/11
StomatitisGastrointestinal disorders3/11
VomitingGastrointestinal disorders3/11

Baseline characteristics

Safety population consisted of all participants in the intent-to-treat (ITT) population who received at least one dose of study drug. ITT population consists of all participants who are enrolled and eligible to enter Stage 2.

Age, Continuous
Age, Continuous(Years)Teduglutide
Mean40.9 ± 12.41
Sex: Female, Male
Sex: Female, Male(Participants)Teduglutide
Female3
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Teduglutide
Hispanic or Latino0
Not Hispanic or Latino11
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Teduglutide
American Indian or Alaska Native0
Asian11
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

5 sites
  • Tohoku University Hospital
    Sendai, Aoba-ku 980-8574, Japan
  • Yokohama Municipal Citizen's Hospital
    Yokohama, Hodogaya-ku 240-8555, Japan
  • Hospital of Hyogo College of Medicine
    Hyogo, Nishinomiya 663-8501, Japan
  • Osaka University Hospital, Department of Gastroenterological Surgery
    Osaka, Suita 565-0871, Japan
  • Osaka University Hospital, Department of Pediatric Surgery
    Osaka, Suita 565-0871, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites, ...)

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Nov 2018, 46 months.

Results were first posted in Nov 2019, 1 year after primary completion.

Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 46 months is above that.

Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2014
First posted
Jan 19, 2015
StartActual
Dec 18, 2014
Primary completionActual
Nov 5, 2018
CompletionActual
Nov 5, 2018
Results first posted
Nov 20, 2019
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02340819
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jan 19, 2015
Start date
Dec 18, 2014
Primary completion
Nov 5, 2018
Completion
Nov 5, 2018
Results posted
Nov 20, 2019
Last update
Jun 9, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion